Horizon Pharma PLC (HZNP) Holdings Lifted by Los Angeles Capital Management & Equity Research Inc.
Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 130.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,395 shares of the biopharmaceutical company’s stock after purchasing an additional 57,360 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned 0.06% of Horizon Pharma worth $1,286,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in HZNP. Paulson & CO. Inc. bought a new position in Horizon Pharma during the 2nd quarter valued at approximately $58,584,000. Dimensional Fund Advisors LP raised its position in shares of Horizon Pharma by 119.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after acquiring an additional 3,409,411 shares in the last quarter. William Blair Investment Management LLC bought a new position in shares of Horizon Pharma in the 2nd quarter worth approximately $23,557,000. Balyasny Asset Management LLC bought a new position in shares of Horizon Pharma in the 2nd quarter worth approximately $13,958,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Horizon Pharma in the 2nd quarter worth approximately $7,147,000. 81.40% of the stock is owned by institutional investors and hedge funds.
Horizon Pharma PLC (HZNP) opened at $13.77 on Monday. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The firm has a market capitalization of $2,256.71, a P/E ratio of 9.98, a P/E/G ratio of 1.17 and a beta of 1.32.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. During the same quarter last year, the company earned $0.70 EPS. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis. equities analysts forecast that Horizon Pharma PLC will post 0.72 earnings per share for the current year.
Several research analysts have recently issued reports on HZNP shares. Zacks Investment Research lowered Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cantor Fitzgerald set a $13.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research report on Monday, July 31st. UBS AG set a $16.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, October 15th. Finally, Mizuho reissued a “hold” rating and issued a $12.00 target price (up previously from $9.00) on shares of Horizon Pharma in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $18.42.
Horizon Pharma Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.